Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fiserv, Inc. related to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 22, 2025 [4]. Group 1: Allegations Against Fiserv - The complaint alleges that Fiserv and its executives made false and misleading statements regarding the performance of its Clover platform, particularly in relation to forced migrations from the older Payeezy platform [6]. - It is claimed that Clover's revenue growth and gross payment volume (GPV) were artificially inflated due to these forced conversions, masking a slowdown in new merchant business [6]. - Following the forced migrations, many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's GPV growth [6]. Group 2: Market Reaction and Stock Performance - On April 24, 2025, Fiserv reported a GPV growth of only 8% for Q1 2025, a decline from 14-17% in 2024, resulting in an 18.5% drop in stock price to $176.90 [7]. - On May 15, 2025, Fiserv announced that GPV growth deceleration would continue throughout 2025, causing a further 16.2% decline in stock price to $159.13 [7]. - On July 23, 2025, Fiserv lowered its full-year organic growth guidance and reported a deceleration in quarterly organic revenue growth to 9% year-over-year, leading to a 13.9% drop in stock price to $143.00 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Charter Communications, Inc. due to allegations of violations of federal securities laws, particularly related to misleading statements about the company's performance and the impact of the Affordable Connectivity Program (ACP) ending [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses exceeding $100,000 in Charter between July 26, 2024, and July 24, 2025, to contact them for discussions about their legal rights [1][4]. - There is a deadline of October 13, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Charter [4][8]. - The complaint alleges that Charter and its executives made false or misleading statements regarding the company's ability to manage the impact of the ACP ending and its overall business performance [6][7]. Group 2: Financial Performance and Market Reaction - Charter reported a decline of 117,000 total internet customers in Q2 2025, compared to a decline of about 100,000 in Q2 2024, after adjusting for the ACP's prior year's impact [7]. - The company's total video customers also decreased by 80,000 during the same period [7]. - Following the release of these financial results, Charter's stock price fell by $70.25 per share, or 18.5%, closing at $309.75 per share on July 25, 2025 [7]. Group 3: Company Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. - The firm is actively seeking information regarding Charter's conduct from whistleblowers, former employees, shareholders, and others [9][10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Unicycive between March 29, 2024, and June 27, 2025, to contact them for legal options [1]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA due to the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is adequate and typical of class members, overseeing the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in LifeMD between May 7, 2025, and August 5, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against LifeMD, with a deadline of October 27, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs [6]. - LifeMD's revised guidance announced on August 5, 2025, projected total revenue in the range of $250 to $255 million, down from previous guidance of $268 to $275 million, leading to a 44.8% stock price drop on August 6, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Replimune Group, Inc. due to allegations of violations of federal securities laws related to misleading statements about the IGNYTE trial and its FDA approval process [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $50,000 in Replimune between November 22, 2024, and July 21, 2025, to discuss their legal rights [1][4]. - A federal securities class action has been filed against Replimune, with a deadline of September 22, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against Replimune - The complaint alleges that Replimune and its executives made false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [6][7]. - Following the FDA's Complete Response Letter on July 22, 2025, Replimune's stock price fell over 73% during intraday trading, indicating significant investor losses [7]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against CTO Realty Growth, Inc. due to allegations of misleading statements regarding the sustainability of dividends and financial practices [3][5]. Group 1: Legal Investigation - The firm is reminding investors of the October 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against CTO [3]. - Investors who suffered losses in CTO between February 18, 2021, and June 24, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Allegations Against CTO - The complaint alleges that CTO and its executives violated federal securities laws by making false statements and failing to disclose that dividends were less sustainable than claimed [5]. - CTO is accused of using deceptive practices to inflate its Adjusted Funds From Operations (AFFO) and overstate the profitability of its Ashford Lane property [5]. - The Wolfpack Research report criticized CTO for not generating enough cash to cover dividends and capital expenditures, leading to a reliance on share dilution [6]. Group 3: Financial Impact - Following the release of the Wolfpack Report, CTO's stock price fell by $0.98, or 5.42%, closing at $17.10 per share on June 25, 2025 [7]. - The report highlighted that CTO has only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million [6].

Core Insights - iRhythm Technologies, Inc. is under investigation by Kahn Swick & Foti, LLC following a Warning Letter from the FDA regarding non-conformities related to its Zio AT System [1][2] - The company faces a securities class action lawsuit for failing to disclose material information, with the court allowing the case to proceed [3] Group 1: FDA Warning and Compliance Issues - On May 30, 2023, iRhythm disclosed receiving a Warning Letter from the FDA concerning non-conformities in medical device regulations, particularly related to the Zio AT System [2] - The FDA's concerns include deficiencies in marketing and capabilities of the Zio AT device, which may pose undisclosed risks to patients [2] Group 2: Legal Proceedings - Following the FDA warning, iRhythm and its executives were sued in a securities class action lawsuit for not disclosing material information during the Class Period [3] - The court has denied the company's motion to dismiss the lawsuit, allowing it to continue, which raises questions about potential breaches of fiduciary duties by the company's officers and directors [3]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging that the company made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, which misled investors about the regulatory timeline [1][2]. Group 1: Lawsuit Details - The lawsuit, Judah Seidman v. Cytokinetics, Incorporated, was initiated in the United States District Court for the Northern District of California for individuals who purchased Cytokinetics common stock between December 27, 2023, and May 6, 2025 [1]. - Class members are notified that they have until November 17, 2025, to request to be appointed as lead plaintiff, although sharing in any recovery does not require serving as a lead plaintiff [4]. Group 2: Allegations Against Cytokinetics - The complaint states that Cytokinetics misrepresented the expected approval timeline from the FDA for aficamten, claiming approval in the second half of 2025 without disclosing risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) [2]. - During an earnings call on May 6, 2025, it was revealed that the company had discussions with the FDA regarding safety monitoring but chose to submit the NDA without a REMS, indicating a reckless decision that misled investors [3]. Group 3: Impact on Investors - As a result of the misleading statements, investors purchased Cytokinetics' common stock at inflated prices and faced significant losses when the truth about the regulatory process was disclosed [4].

Core Insights - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with a focus on its sales growth and inventory practices [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration and strong demand across all channels, attributed to distribution expansion and promotional activities [2]. Group 2: Sales Growth Concerns - There are concerns that the sales growth during the relevant period may have been artificially inflated due to temporary trade inventory loading at key retailers rather than sustainable consumer demand [2]. - On May 5, 2025, BellRing disclosed that several key retailers had reduced their weeks of supply, which would negatively impact growth in Q3 2025 [3]. Group 3: Stock Performance - Following the May 5 announcement, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company reported disappointing quarterly consumption of Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - A class action lawsuit has been filed against Neogen Corporation for alleged misrepresentations regarding the integration of 3M and its impact on the company's financial health during the class period from January 5, 2023, to June 3, 2025 [2][4]. Summary by Sections Legal Action - The lawsuit is filed in the United States District Court for the Western District of Michigan on behalf of all individuals and entities who purchased Neogen common stock during the specified class period [2]. - Investors have until September 16, 2025, to apply to be appointed as lead plaintiff in the lawsuit [2]. Allegations - The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, claiming that Neogen's management misrepresented the status of the 3M integration and failed to disclose its negative financial impacts [4]. - Defendants allegedly issued false and misleading statements, leading investors to believe that the integration was progressing smoothly while downplaying integration inefficiencies [4]. Financial Disclosures - On January 10, 2025, Neogen disclosed a GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, leading to a 5% decline in stock price to $12.36 per share [5]. - In the following quarter, on April 9, 2025, Neogen reported a 3.4% revenue decline to $221 million and cut its FY25 guidance, resulting in a 28% drop in stock price to $5.02 per share [6]. - On June 4, 2025, Neogen projected an EBITDA margin drop to the high teens from the previous quarter's 22%, causing an additional 17% decline in stock price to $4.96 per share [7].